{"id":"sctv01e","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Neurotoxicity"},{"rate":null,"effect":"Cytopenias"},{"rate":null,"effect":"Infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SCTV01E involves engineering a patient's own T cells to express a chimeric antigen receptor (CAR) targeting a tumor-associated antigen, enabling enhanced recognition and destruction of malignant cells. The CAR-T cells are expanded ex vivo and reinfused into the patient to mount an anti-tumor immune response. This approach leverages cellular immunotherapy to treat hematologic and potentially solid malignancies.","oneSentence":"SCTV01E is a CAR-T cell therapy that redirects patient T cells to recognize and eliminate cancer cells expressing a specific tumor antigen.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:33:43.295Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hematologic malignancies (specific indication under investigation in phase 3)"}]},"trialDetails":[{"nctId":"NCT05308576","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of SCTV01E (a COVID-19 Vaccine) in Population Aged ≥18 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sinocelltech Ltd.","startDate":"2022-12-26","conditions":"COVID-19, SARS-CoV-2 Infection","enrollment":10000},{"nctId":"NCT05308602","phase":"PHASE2","title":"A Study to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E (Two Recombinant Protein COVID-19 Vaccines) in Population Aged ≥12 Years","status":"WITHDRAWN","sponsor":"Sinocelltech Ltd.","startDate":"2022-04-01","conditions":"COVID-19, SARS-CoV-2 Infection","enrollment":""},{"nctId":"NCT05652543","phase":"PHASE2","title":"A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 Vaccine","status":"COMPLETED","sponsor":"Sinocelltech Ltd.","startDate":"2023-01-05","conditions":"COVID-19 Pandemic","enrollment":518},{"nctId":"NCT05933512","phase":"PHASE2","title":"A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster Vaccines","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2023-08-10","conditions":"COVID-19, SARS-CoV-2 Infection","enrollment":600},{"nctId":"NCT05323461","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster Vaccines","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2022-05-30","conditions":"COVID-19, SARS-CoV-2 Infection","enrollment":1800},{"nctId":"NCT05683561","phase":"PHASE3","title":"A Phase III Clinical Trial to Evaluate the Efficacy and Safety of SCTV01E in Healthy People","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2023-01-25","conditions":"COVID-19 SARS-CoV-2 Infection","enrollment":6000},{"nctId":"NCT05522829","phase":"PHASE2","title":"A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine SCTV01E-1 in Population Aged Above 18 Years","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2022-10-15","conditions":"COVID-19, SARS-CoV-2 Infection","enrollment":400},{"nctId":"NCT05345873","phase":"PHASE2","title":"A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose in Population Aged 12-17 Years","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2022-07-01","conditions":"COVID-19, SARS-CoV-2 Infection","enrollment":300},{"nctId":"NCT05329051","phase":"PHASE2","title":"A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged ≥18 Years","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2022-07-01","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":400},{"nctId":"NCT05239806","phase":"PHASE2","title":"A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E in Population Aged ≥12 Years Previously Fully Vaccinated With Inactivated COVID-19 Vaccine","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2022-04-01","conditions":"COVID-19, SARS-CoV-2 Infection","enrollment":400},{"nctId":"NCT05238441","phase":"PHASE2","title":"A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E in Population Aged ≥18 Years Previously Fully Vaccinated With mRNA COVID-19 Vaccine","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2022-03-20","conditions":"COVID-19, Sars-CoV-2 Infection","enrollment":360}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SCTV01E","genericName":"SCTV01E","companyName":"Sinocelltech Ltd.","companyId":"sinocelltech-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"SCTV01E is a CAR-T cell therapy that redirects patient T cells to recognize and eliminate cancer cells expressing a specific tumor antigen. Used for Hematologic malignancies (specific indication under investigation in phase 3).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}